Home/Pipeline/Inclisiran (LEQVIO)

Inclisiran (LEQVIO)

Hypercholesterolemia

ApprovedCommercial - Partnered

Key Facts

Indication

Hypercholesterolemia

Phase

Approved

Status

Commercial - Partnered

Company

Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

Founded in 2002, Alnylam Pharmaceuticals is a leading biopharmaceutical company that pioneered the RNAi therapeutics revolution. The company leverages RNA interference technology to selectively silence genes that cause or contribute to disease, offering a fundamentally different approach to treating genetic disorders. With multiple approved therapies and a strong pipeline focused on rare diseases, Alnylam has established itself as the definitive leader in RNAi therapeutics with global reach and operations.

View full company profile

Therapeutic Areas

Rare Diseases Genetic Disorders Amyloidosis Porphyria Primary Hyperoxaluria Cardiovascular Neurology

Other Hypercholesterolemia Drugs

Drug	Company	Phase	Status
VXX-401	Vaxxinity	Phase 1	Active
Atorvastatin Oral Liquid Suspension	CMP Pharma	Approved	Marketed